WASHINGTON, DC—A sirolimus drug-coated balloon (DCB) is noninferior to paclitaxel-coated DCBs for the treatment of femoropopliteal artery disease, according to data from the SIRONA trial, the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback